📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Module 1 (EU) — IMPD Summary (OBX-319)

Document ID: M1-IMPD
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): CTR 536/2014

Investigational Medicinal Product Dossier (IMPD) — OBX-319

EU clinical-trial dossier for OBX-319 (bispecific monoclonal antibody). Summarises the quality (S/P), non-clinical, and clinical data supporting the trial in Systemic Lupus Erythematosus (moderate-to-severe active), cross-referencing Modules 3-5. Directive 2001/20/EC; CTR 536/2014; ICH.

OBX-319 is a humanised IgG1 bispecific monoclonal antibody that binds CD19 and CD20 on the B-cell surface, produced by recombinant Chinese hamster ovary (CHO) cell culture and administered subcutaneously. Its two antigen-binding arms engage CD19 and CD20 simultaneously, driving broad, Fc-effector-mediated depletion of the B-cell compartment through antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and complement-dependent cytotoxicity (CDC). Dual targeting is intended to extend depletion across B-cell subsets that lie beyond the reach of single-target anti-CD20 agents — notably CD20-low/negative plasmablasts and early B-lineage progenitors that retain CD19 — providing a deeper and more uniform reset of the autoreactive B-cell pool that drives lupus pathology. The Sponsor is Virtual Biopharma Inc. The product is an investigational medicinal product under CTR 536/2014, manufactured to EU GMP (including Annex 1 for the sterile drug product); the quality, non-clinical and clinical development is aligned with the applicable ICH guidelines, in particular Q5A(R2) (viral safety), Q5C (biotechnological product stability), Q6B (specifications) and S6(R1) (non-clinical evaluation of biotechnology-derived pharmaceuticals). The corresponding marketing application in the United States is anticipated to proceed as a Biologics License Application under 21 CFR 601.

Quality — Drug Substance (Module 3.2.S)

General information and characterisation (S.1, S.3). OBX-319 is a heterodimeric, humanised IgG1-format bispecific antibody of approximately 150 kDa. Correct heavy-chain heterodimerisation and cognate heavy-/light-chain pairing are enforced by complementary Fc interface ("knob-into-hole"-type) and chain-pairing engineering, so that each molecule presents one anti-CD19 and one anti-CD20 Fab arm (a 1+1 architecture). The molecule carries the conserved N-linked glycosylation site at Fc Asn297, which modulates Fc-effector function. Extensive physicochemical and functional characterisation is provided in Module 3.2.S.3: intact- and subunit-mass spectrometry, peptide mapping with disulfide-bond assignment, confirmation and quantification of correctly assembled bispecific versus product-related mispaired and homodimeric species, N-glycan profiling, charge- and size-variant distribution, and functional confirmation of simultaneous dual-antigen binding.

Manufacture and control of adventitious agents (S.2). The drug substance is expressed in a CHO cell line under a two-tiered, fully characterised Master and Working Cell Bank system established and tested in accordance with ICH Q5A(R2), Q5B and Q5D, using chemically defined, animal-component-free media (TSE/adventitious-agent risk controlled). Production is by fed-batch cell culture followed by clarification (centrifugation/depth filtration). Downstream purification comprises Protein A affinity capture as the primary step, low-pH viral inactivation, and orthogonal polishing chromatography (ion-exchange and mixed-mode) designed to resolve product-related variants — including mispaired chains, aggregates and charge variants — followed by dedicated small-virus-retentive nanofiltration and ultrafiltration/diafiltration into the formulation buffer. Viral safety is assured by the combination of cell-substrate testing, raw-material controls and a dedicated viral-clearance study demonstrating robust, orthogonal reduction across the purification train, consistent with ICH Q5A(R2). In-process controls, hold times and the process-validation strategy are described in 3.2.S.2.

Control of drug substance and stability (S.4, S.7). The release and stability specification (3.2.S.4.1) follows ICH Q6B and includes: identity by binding to both CD19 and CD20; potency by a cell-based B-cell-depletion/ADCC bioassay together with dual-antigen binding; purity and product-related impurities by size-exclusion chromatography (aggregates/high-molecular-weight species), reduced and non-reduced CE-SDS (fragments and correct chain assembly) and imaged capillary isoelectric focusing/ion-exchange (charge variants); process-related impurities including residual host-cell protein, residual host-cell DNA by qPCR and residual Protein A; plus endotoxin, bioburden, protein content and appearance. Stability is evaluated under ICH Q5C using real-time (2-8 °C), accelerated and stress conditions to support the drug-substance storage condition, retest period and shelf life; degradation pathways (aggregation, fragmentation, deamidation/isomerisation, oxidation) are monitored by stability-indicating methods.

Quality — Drug Product (Module 3.2.P)

The drug product is a sterile solution for subcutaneous injection. The formulation employs a histidine-based buffer with a stabilising sugar (sucrose) and polysorbate 80 as surfactant at a mildly acidic pH, optimised for a high-concentration subcutaneous presentation with acceptable viscosity, colloidal stability and container-closure compatibility; the definitive composition, fill and pharmaceutical-development rationale (including extractables/leachables and in-use stability) are provided in 3.2.P.1-P.2. Two dose strengths are supplied to support the clinical dose levels evaluated in the trial (designated High and Low), together with a matching placebo of identical appearance and presentation to preserve the double blind. Aseptic fill-finish is performed under EU GMP Annex 1. The drug-product release and stability specification (3.2.P.5.1) includes appearance, pH, protein content, potency, purity by SEC and CE-SDS, sub-visible particulate matter (Ph. Eur. 2.9.19), extractable volume, container-closure integrity, sterility and bacterial endotoxin. Drug-product stability is conducted per ICH Q5C to define shelf life and storage (2-8 °C), with an assessment of in-use stability supporting subcutaneous administration.

Non-clinical Summary (Module 4)

Primary pharmacology. The pharmacological rationale rests on simultaneous engagement of CD19 and CD20 and consequent Fc-effector-mediated depletion of B cells. In vitro, OBX-319 mediates potent B-cell killing via ADCC, ADCP and CDC; in vivo, subcutaneous administration produces marked peripheral B-cell depletion. Dual targeting broadens the depletable repertoire relative to CD20-only agents, encompassing CD19-positive, CD20-low progenitors and plasmablasts implicated in autoantibody production.

Species selection (ICH S6(R1)). The cynomolgus monkey is the sole pharmacologically relevant species: both target epitopes are conserved and OBX-319 binds cynomolgus CD19 and CD20 with pharmacological engagement, whereas the antibody does not cross-react with rodent orthologues, rendering rodent studies uninformative. Consequently the non-clinical programme is built around the cynomolgus monkey, supported by a tissue cross-reactivity assessment on human and cynomolgus tissue panels.

Pharmacokinetics. OBX-319 exhibits target-mediated drug disposition (TMDD): clearance is nonlinear and saturable, dominated by target-mediated elimination at low concentrations and becoming more linear once target is saturated at higher exposures, with subcutaneous absorption and a long terminal half-life characteristic of an FcRn-recycled IgG1. Anti-drug antibodies (ADA) are monitored, as immunogenicity is relevant for this modality and can affect exposure, pharmacodynamics and safety.

Toxicology and studies not conducted. GLP repeat-dose subcutaneous toxicology studies with recovery periods are conducted in the cynomolgus monkey; the anticipated principal findings are exaggerated pharmacology (sustained B-cell depletion with secondary reductions in circulating immunoglobulins) and immunogenicity, with safety-pharmacology endpoints (cardiovascular, respiratory and central-nervous-system) integrated into the repeat-dose design in line with ICH S6(R1). Reproductive and developmental risk (including the potential for B-cell depletion in offspring) is addressed by an enhanced pre-/post-natal development evaluation as warranted. Consistent with ICH S6(R1) and the nature of a large monoclonal antibody, genotoxicity studies (ICH S2(R1) not applicable to biotechnology-derived proteins), carcinogenicity studies (ICH S1 not warranted; addressed by weight-of-evidence), and dedicated hERG assays and thorough-QT/ICH S7B-E14 cardiac studies are not conducted, because an antibody of this size does not interact with cardiac ion channels and no such liability is expected.

Clinical Summary and Previous Human Experience (Module 5)

Earlier-phase clinical experience established the subcutaneous pharmacokinetic/pharmacodynamic profile of OBX-319, confirmed dose-dependent peripheral B-cell depletion and characterised initial tolerability (cross-referenced to Module 5). The pivotal experience supporting this trial is study OBX319-301.

Study OBX319-301 — design. A Phase 3, randomised, double-blind, placebo-controlled, 1:1:1, 52-week trial on a background of standard of care in adults with moderate-to-severe active SLE. A total of 480 patients were randomised (162 High / 158 Low / 160 Placebo), with a mean baseline SLEDAI-2K of approximately 11.

Efficacy. The primary endpoint — an SRI-4 response with attainment of low disease activity (SLEDAI-2K ≤ 4) at Week 52 — was met: 52.4% (76/145) on the High dose and 33.8% (49/145) on the Low dose versus 6.0% (9/150) on placebo. The key secondary endpoint, LS-mean change from baseline in SLEDAI-2K, was −6.37 (High) and −5.62 (Low) versus −3.46 (placebo), corresponding to placebo-adjusted differences of −2.91 (High) and −2.17 (Low). Efficacy was dose-ordered and consistent across the primary and secondary measures.

Pharmacodynamics and biomarkers. Both active arms produced near-complete depletion of peripheral CD19+ B cells (from approximately 210 to approximately 7 cells/µL), with no meaningful change on placebo. Response was accompanied by falling anti-dsDNA autoantibody titres and normalisation of complement C3/C4, providing direct mechanistic confirmation of target engagement and immunological modulation tracking the clinical benefit.

Safety. The observed and anticipated safety profile is that of B-cell-depleting therapy. Serious and opportunistic infections and hypogammaglobulinaemia — the downstream consequence of sustained B-cell depletion and reduced immunoglobulins — are the key identified risks and are managed through infection screening, immunoglobulin monitoring, vaccination guidance and protocol-defined risk-minimisation measures. Injection-site/administration reactions and immunogenicity (ADA) are expected class effects and are monitored. No thyroid-related safety signal is relevant to OBX-319; thyroid and medullary-cell considerations pertain to the GLP-1 receptor agonist class and do not apply to this antibody.

Overall Benefit-Risk Assessment

The totality of the data supports a positive benefit-risk balance for continued clinical development. Quality is controlled to ICH Q5A(R2)/Q5C/Q6B standards with bispecific-specific characterisation of correct chain assembly and dual-target potency; the non-clinical package is scientifically appropriate to the modality under ICH S6(R1), with the omission of genotoxicity, carcinogenicity and cardiac ion-channel/QT studies fully justified for a monoclonal antibody. Clinically, OBX-319 delivered robust, dose-ordered efficacy on the primary SRI-4/low-disease-activity endpoint and on SLEDAI-2K reduction, corroborated by near-complete B-cell depletion, declining anti-dsDNA and complement normalisation. The principal risks — serious/opportunistic infection, hypogammaglobulinaemia, administration reactions and immunogenicity — are identified, monitorable and manageable within the trial's risk-minimisation framework, consistent with the risk-management plan and pharmacovigilance strategy.